Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361678 | 0.79 | PDPK1 (0.39) | HTTPTK2MAPTCHEK1RET | |
| SCHEMBL29684443 | 0.79 | NOS1 (0.39) | NOS1HTTPTK2 | |
| SCHEMBL29863669 | 0.76 | NOS1 (0.37) | NOS1HTTPTK2 | |
| SCHEMBL4838398 | 0.76 | NOS1 (0.37) | NOS1HTTPTK2 | |
| SCHEMBL4106173 | 0.72 | DPP4 (0.43) | NOS1HTTPTK2MAPTCSNK1A1 | |
| SCHEMBL30774307 | 0.72 | HTT (0.36) | NOS1HTTPTK2CHEK1 | |
| SCHEMBL22119097 | 0.72 | HTT (0.36) | NOS1HTTPTK2 | |
| SCHEMBL29864632 | 0.72 | NOS1 (0.34) | NOS1HTTPTK2 | |
| SCHEMBL15650689 | 0.69 | ADORA2A (0.44) | HTT | |
| SCHEMBL560806 | 0.68 | RET (0.52) | NOS1HTTMAPTCHEK1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390890-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007069924-A1 | DEAZAPURINE ANALOGS OF 4'-AZA-L-NUCLEOSIDES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-06-21 | — | — | WO | disclosed |
| US-7211653-B2 | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6803455-B2 | PYRROLO(3,2-D)PYRIMIDIN-7-YL)-1,4-IMINO-D-RIBITOL DERIVATIVES; FOR SUPPRESSION OF T-CELL FUNCTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-10-12 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026936-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | NOS1 4035/4885HTT 1391/4885PTK2 3836/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | NOS1 2491/4885HTT 1403/4885PTK2 4060/4885 |
| US-20070197561-A1 | Inhibitors of nucleoside metabolism | CFH, CBR3, SLCO2B1 | NOS1 4035/4885HTT 1391/4885PTK2 3836/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | NOS1 3125/4885HTT 888/4885PTK2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.